MA54900A - Composés inhibiteurs de l'échangeur sodium-hydrogène 3 - Google Patents

Composés inhibiteurs de l'échangeur sodium-hydrogène 3

Info

Publication number
MA54900A
MA54900A MA054900A MA54900A MA54900A MA 54900 A MA54900 A MA 54900A MA 054900 A MA054900 A MA 054900A MA 54900 A MA54900 A MA 54900A MA 54900 A MA54900 A MA 54900A
Authority
MA
Morocco
Prior art keywords
sodium
inhibitor compounds
hydrogen exchanger
exchanger
hydrogen
Prior art date
Application number
MA054900A
Other languages
English (en)
Inventor
Kostas Gavardinas
Prabhakar Jadhav
Xiaojun Wang
John Rowley Wetterau
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA54900A publication Critical patent/MA54900A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA054900A 2019-05-16 2020-05-08 Composés inhibiteurs de l'échangeur sodium-hydrogène 3 MA54900A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962848652P 2019-05-16 2019-05-16

Publications (1)

Publication Number Publication Date
MA54900A true MA54900A (fr) 2022-03-23

Family

ID=70919092

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054900A MA54900A (fr) 2019-05-16 2020-05-08 Composés inhibiteurs de l'échangeur sodium-hydrogène 3

Country Status (14)

Country Link
US (2) US12428377B2 (fr)
EP (1) EP3921308B1 (fr)
JP (1) JP7194848B2 (fr)
KR (2) KR102681183B1 (fr)
CN (1) CN113784956B (fr)
AU (1) AU2020276204B2 (fr)
BR (1) BR112021019936A2 (fr)
EA (1) EA202192414A1 (fr)
ES (1) ES2927100T3 (fr)
IL (1) IL287963B2 (fr)
MA (1) MA54900A (fr)
MX (1) MX2021013771A (fr)
SA (1) SA521430837B1 (fr)
WO (1) WO2020231770A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805202A (zh) * 2021-01-28 2022-07-29 江西济民可信集团有限公司 苯磺酰胺类化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10312963A1 (de) 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
KR20170091783A (ko) 2008-12-31 2017-08-09 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
SMT201900386T1 (it) * 2013-04-12 2019-09-09 Ardelyx Inc Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato
CA3033628C (fr) * 2016-08-15 2021-01-12 Eli Lilly And Company Derives de thiophene condenses utiles en tant qu'inhibiteurs de napi-iib
AU2018205400C1 (en) * 2017-01-09 2026-01-15 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders

Also Published As

Publication number Publication date
CA3136060A1 (fr) 2020-11-19
IL287963B1 (en) 2024-09-01
US20250382271A1 (en) 2025-12-18
CN113784956A (zh) 2021-12-10
WO2020231770A1 (fr) 2020-11-19
MX2021013771A (es) 2021-12-10
SA521430837B1 (ar) 2024-10-29
US12428377B2 (en) 2025-09-30
JP2022531438A (ja) 2022-07-06
EP3921308B1 (fr) 2022-08-03
IL287963A (en) 2022-01-01
BR112021019936A2 (pt) 2021-12-07
CN113784956B (zh) 2025-03-11
AU2020276204B2 (en) 2022-05-19
KR102681183B1 (ko) 2024-07-04
EA202192414A1 (ru) 2022-03-02
AU2020276204A1 (en) 2021-10-07
IL287963B2 (en) 2025-01-01
KR20240110086A (ko) 2024-07-12
KR20210151911A (ko) 2021-12-14
EP3921308A1 (fr) 2021-12-15
ES2927100T3 (es) 2022-11-02
US20220213042A1 (en) 2022-07-07
JP7194848B2 (ja) 2022-12-22

Similar Documents

Publication Publication Date Title
MA52939A (fr) Composés inhibiteurs d'oga
MA52942A (fr) Composés inhibiteurs d'oga
MA52493A (fr) Sels d'un inhibiteur de fgfr
EP3737672A4 (fr) Composés benzamide
MA47420A (fr) Composés inhibiteurs d'oga
EP3919491A4 (fr) Inhibiteur d'akt
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
DK4045863T3 (da) Varmeveksler
EP4080151C0 (fr) Échangeur de chaleur
EP3908319A4 (fr) Composés inhibiteurs de métalloenzyme
MA54521A (fr) Dérivés d'oxopyridine substitués
PL3971508T3 (pl) Wymiennik ciepła
EP3993782A4 (fr) Compositions d'endoxifène à libération prolongée
EP3820980A4 (fr) Compositions d'esterquats
EP4005306A4 (fr) Configuration d'intervalle de duplex intégral
EP4003986A4 (fr) Composés inhibiteurs
EP3833342A4 (fr) Composés d'imidazotétrazine
EP4206080A4 (fr) Dégazeur
EP3978855A4 (fr) Échangeur de chaleur
EP3951308A4 (fr) Échangeur de chaleur
MA52934A (fr) Composés inhibiteurs de l'oga
MA52937A (fr) Composés inhibiteurs d'oga
EP3935037A4 (fr) Utilisation de composés de 8,9-dihydrocannabidiol
EP3926284A4 (fr) Échangeur de chaleur
IL287963A (en) Compounds of sodium-hydrogen exchanger inhibitor 3